J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial

Johnson & Johnson reported positive topline Phase 3 MonumenTAL-6 results, showing that two Tecvayli- and Talvey-based regimens significantly improved progression-free survival in adults with relapsed or refractory multiple myeloma. The update supports a favorable efficacy read-through, but details on effect size and durability were not provided in the excerpt.

Analysis

Johnson & Johnson reported positive topline Phase 3 MonumenTAL-6 results, showing that two Tecvayli- and Talvey-based regimens significantly improved progression-free survival in adults with relapsed or refractory multiple myeloma. The update supports a favorable efficacy read-through, but details on effect size and durability were not provided in the excerpt.